Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107792

Measurement of Circulating Desialylated Glycoproteins and Correlation with Hepatocellular Damage

James S. Marshall, Allan M. Green, Jack Pensky, Stanford Williams, Arthur Zinn, and Don M. Carlson

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Marshall, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Green, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Pensky, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Williams, S. in: JCI | PubMed | Google Scholar

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Zinn, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Find articles by Carlson, D. in: JCI | PubMed | Google Scholar

Published September 1, 1974 - More info

Published in Volume 54, Issue 3 on September 1, 1974
J Clin Invest. 1974;54(3):555–562. https://doi.org/10.1172/JCI107792.
© 1974 The American Society for Clinical Investigation
Published September 1, 1974 - Version history
View PDF
Abstract

Addition of increasing amounts of 125I-labeled desialylated thyroxine-binding globulin (DTBG) to hepatic cell membranes resulted in a progressive increase in binding. Saturability of membrane sites was indicated by a concentration beyond which further increases in [125I]DTBG resulted in no further binding. The binding curve for [125I]DTBG was similar to binding curves of desialylated orosomucoid, fetuin, and ceruloplasmin.

An inhibition assay system using hepatic cell membranes showed that desialylated orosomucoid had a greater affinity for membrane binding sites than did DTBG but desialylated fetuin and ceruloplasmin bound less avidly than DTBG.

Serum from normal persons and patients with a variety of illnesses was tested for its ability to inhibit [125I]DTBG binding. The inhibitory activity of 1 ml of normal serum was equivalent to that of 0.2-2 μg DTBG. Patients with Laënnec's cirrhosis, biliary cirrhosis, and hepatic metastases had greatly increased inhibitory activity in their serum. Patients with jaundice due to extrahepatic obstruction had inhibitory activity not significantly different from that found in normal serum.

Column chromatography of normal serum on Sephadex G-200 resulted in inhibitory activity throughout the range of protein molecular weight. Desialylation of normal serum with neuraminidase enhanced the inhibitory activity but did not change the distribution of the activity. Gel chromatography of cirrhotic serum showed markedly increased inhibitory activity associated with the macroglobulins and the 4.5S peak and a new peak of inhibitory activity in the low molecular weight area was also seen.

Inhibition of desialylated glycoprotein binding to liver cell membranes by serum from patients with hepatocellular disease raises the possibility that desialylated serum glycoproteins accumulate in the circulation and that patients with compromised hepatocellular function may no longer be able to clear them from the circulation. Alternatively, accumulation of desialylated glycoproteins in the circulation could result from defective protein synthesis by the diseased liver.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 555
page 555
icon of scanned page 556
page 556
icon of scanned page 557
page 557
icon of scanned page 558
page 558
icon of scanned page 559
page 559
icon of scanned page 560
page 560
icon of scanned page 561
page 561
icon of scanned page 562
page 562
Version history
  • Version 1 (September 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts